Physician
Pediatric Hematology & Oncology
Dr. Brigitte C. Widemann, MD
|
|
Give Review
Brigitte Widemann works in the field of Pediatric Hematology & Oncology. Brigitte Widemann is a published doctor as well. She has 95 publications published. The latest was: Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader.
Publications
- Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-hum...
- Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
- Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children an...
- Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group.
- Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
- Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model.
- Development and Validation of the English Pain Interference Index and Pain Interference Index-Parent Report.
- Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging.
- Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study.
- Genetic Modifiers of Neurofibromatosis Type 1-Associated Café-au-Lait Macule Count Identified Using Multi-platform Analysis.
- Update from the 2013 international neurofibromatosis conference.
- Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application.
- Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children's oncology group phase I consortium.
- Age dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.
- Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
- CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
- Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neur...
- Attitudes About Internet Support Groups Among Adolescents and Young Adults with Neurofibromatosis Type 1 and their Parents.
- Achieving consensus for clinical trials: The REiNS International Collaboration.
- Efficacy of Glucarpidase (Carboxypeptidase G2) in Patients with Acute Kidney Injury After High-Dose Methotrexate Therapy.
- PET-guided biopsy with needle navigation facilitates diagnosis of angiosarcoma in neurofibromatosis type 1.
- Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma.
- Using a lower dose of glucarpidase to reduce plasma levels of methotrexate.
- Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
- Visual Outcomes in Children With Neurofibromatosis Type 1 and Orbitotemporal Plexiform Neurofibromas.
- MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
- 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) o...
- Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.
- Bone mineral density in children and young adults with neurofibromatosis type 1.
- Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
- Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
- Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials.
- Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Child...
- Experiences of families with a child, adolescent, or young adult with neurofibromatosis type 1 and plexiform neurofibroma evaluated for clinical trials participation a...
- A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents w...
- The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
- Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
- Pediatric phase I trial design using maximum target inhibition as the primary endpoint.
- Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
- Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
- Sorafenib and sunitinib.
- Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
- Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.
- Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
- Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.
- A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
- Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leuke...
- Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.
- A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
- Understanding and managing methotrexate nephrotoxicity.
- Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexif...
- Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
- Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.
- High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
- Merlin PAKs a punch.
- Evaluation and treatment of fever in the non-neutropenic child with cancer.
- Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
- Model for Concomitant Microdialysis Sampling of the Pons and Cerebral Cortex in Rhesus Macaques (Macaca mulatta).
- Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model.
- The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression.
- A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
- The bioavailability of oral methotrexate in children with inflammatory bowel disease.
- Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children''s Oncology Group.
- Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging.
- The fibrous metaphyseal defect in early stage. Differential diagnosis to metaphysitis.
- Dysplastic gangliocytoma of cerebellum in a newborn. Diagnosis by ultrasonography and MRI.
- [Bone marrow metastases of neuroblastoma: MRT in comparison with bone marrow cytology and mIBG scintigraphy].
- Mycoplasmal pneumonias in childhood. Roentgen features, differential diagnosis and review of literature.
- [Is hip sonography meaningful as a screening method?].
- [Is hip sonography in premature infants necessary as a screening procedure?].
- Cytomegalovirus ureteritis as a cause of renal failure in a child infected with the human immunodeficiency virus.
- Airway endoscopy in the diagnosis and treatment of bacterial tracheitis in children.
- In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment.
- Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine.
- Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates.
- Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors.
- Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.
- Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
- Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
- 111In-Octreotide Scintigraphy for Identification of Metastatic Medullary Thyroid Carcinoma in Children and Adolescents.
- Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
- Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas.
- Meeting report: pharmacology in pediatric oncology. Summary of the 10th international expert meeting of the Kind Philipp Foundation for leukemia research, June 10 - 13...
- A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National C...
- The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model.
- Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid.
- Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NC...
- Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2.
- Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
- Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
- Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader.
- Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.
- Clinical drug development for childhood cancers.
- NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Education
-
National Capital Consortium
Helpful Reviews
Similar Doctors
|
|
Dr. Allen I. Stering, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vemulkonda K. Rao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth H. Lieuw, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Caterina P. Minniti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul T. Peebles, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary J. Herden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicole M. Giamanco, MD
This Doctor is OpenDoctor Recommended.
|